Barclays maintains Jazz Pharmaceuticals at Overweight
Barclays maintained its Overweight rating on Jazz Pharmaceuticals, No price target change or additional details were provided in the feed.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.